CAR T-cell therapy: a new era in cancer immunotherapy
AN Miliotou, LC Papadopoulou - Current pharmaceutical …, 2018 - ingentaconnect.com
Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …
number of conventional cytotoxic approaches for neoplastic diseases has been developed …
[HTML][HTML] The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
L Long, X Zhang, F Chen, Q Pan… - Genes & …, 2018 - ncbi.nlm.nih.gov
Cancer immunotherapy and tumor microenvironment have been at the forefront of research
over the past decades. Targeting immune checkpoints especially programmed death 1 (PD …
over the past decades. Targeting immune checkpoints especially programmed death 1 (PD …
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
The development of human cancer is a multistep process characterized by the accumulation
of genetic and epigenetic alterations that drive or reflect tumour progression. These changes …
of genetic and epigenetic alterations that drive or reflect tumour progression. These changes …
Interleukin-2 and regulatory T cells in rheumatic diseases
Failure of regulatory T (Treg) cells to properly control immune responses leads invariably to
autoimmunity and organ damage. Decreased numbers or impaired function of Treg cells …
autoimmunity and organ damage. Decreased numbers or impaired function of Treg cells …
Mechanisms of immune evasion in bladder cancer
PL Crispen, S Kusmartsev - Cancer Immunology, Immunotherapy, 2020 - Springer
With the introduction of multiple new agents, the role of immunotherapy is rapidly expanding
across all malignancies. Bladder cancer is known to be immunogenic and is responsive to …
across all malignancies. Bladder cancer is known to be immunogenic and is responsive to …
Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression
E Gianchecchi, A Fierabracci - Frontiers in immunology, 2018 - frontiersin.org
Regulatory T (Treg) cells represent a subpopulation of suppressor CD4+ T cells critically
involved in the establishment of peripheral tolerance through the inhibition of effector T (Teff) …
involved in the establishment of peripheral tolerance through the inhibition of effector T (Teff) …
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors
EK Moon, LC Wang, DV Dolfi, CB Wilson… - Clinical cancer …, 2014 - AACR
Purpose: Immunotherapy using vaccines or adoptively transferred tumor-infiltrating
lymphocytes (TIL) is limited by T-cell functional inactivation within the solid tumor …
lymphocytes (TIL) is limited by T-cell functional inactivation within the solid tumor …
Regulatory T cells in nonlymphoid tissues
D Burzyn, C Benoist, D Mathis - Nature immunology, 2013 - nature.com
Abstract Both Foxp3+ CD4+ regulatory T cells (Treg cells) and local immune responses in
nonlymphoid tissues have long been recognized as important elements of a well …
nonlymphoid tissues have long been recognized as important elements of a well …
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas
Recently, the possibility of PD1 pathway-targeted therapy has been extensively studied in
various human malignant tumors. However, no previous study has investigated their …
various human malignant tumors. However, no previous study has investigated their …
[HTML][HTML] A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
The last several years have witnessed exciting progress in the development of
immunotherapy for the treatment of cancer. This has been due in great part to the …
immunotherapy for the treatment of cancer. This has been due in great part to the …